Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 1, 2017, Pages

  Andriolo, Brenda N G ^a   Andriolo, Regis B ^b   Salomão, Reinaldo ^c   Atallah, Álvaro N ^a  

^a Brazilian Cochrane Centre   (Brazil)

^b UNIVERSIDADE DO ESTADO DO PARÁ   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN;

ADULT; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; CINAHL; DRUG EFFICACY; DRUG SAFETY; EMBASE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFECTION; INTENSIVE CARE UNIT; LENGTH OF STAY; MEDLINE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFECTION; REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; META ANALYSIS; SHOCK, SEPTIC; TIME FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; BIOMARKERS; CALCITONIN; HUMANS; INTENSIVE CARE UNITS; PATIENT DISCHARGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SHOCK, SEPTIC; TIME FACTORS;

EID: 85009833812     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010959.pub2     Document Type: Review

References (104)

1. Annane D, Maxime V, Faller JP, Mezher C, Clec'h C, Martel P, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open 2013;3(2):e002186. [4780890; PUBMED: 23418298]
2. Deliberato RO, Marra AR, Sanches PR, Martino MD, Ferreira CE, Pasternak J, et al. Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagnostic Microbiology and Infectious Disease 2013;76(3):266-71. [4780892; PUBMED: 23711530]
3. Dharaniyadewi D, Lie KC, Sukmana N, Rumende CM. Effect of semi-quantitative procalcitonin assay on the adequacy of empirical antibiotics and mortality in septic patients. Critical Care 2013;17:10. [4780894; DOI: 10.1186/cc12915]
4. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care (London, England) 2009;13(3):R83. [4780896; PUBMED: 19493352]
5. Liu BH, Li HF, Lei Y, Zhao SX, Sun ML. Clinical significance of dynamic monitoring of procalcitonin in guiding the use of antibiotics in patients with sepsis in ICU Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2013;25(11):690-3. [4780898; PUBMED: 24225216]
6. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2008;177(5):498-505. [4780900; PUBMED: 18096708]
7. Oliveira CF, Botoni FA, Oliveira CA, Pereira HAC, Padua M, Nobre V. The usefulness of C-reactive protein (CRP) compared to procalcitonin (PCT) to reduce antibiotic exposure in critically ill patients with sepsis: a pilot study. Intensive Care Medicine. 2011; Vol. 37:S200. [4780902; CN-01035397]
8. Oliveira CF, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Critical Care Medicine 2013;41(10):2336-43. [4780903; PUBMED: 23921272]
9. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbeck's Archives of Surgery 2009;394(2):221-6. [4780905; PUBMED: 19034493]
10. Shehabi Y, Rachakonda KS, Bailey MJ, Peake S. Reply. No significant reduction in antibiotic treatment using a procalcitonin algorithm with low cutoff value in the intensive care unit?. American Journal of Respiratory and Critical Care Medicine 2015;191(7):859-60. [4780907]
11. Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2014;190(10):1102-10. [4780908; PUBMED: 25295709]
12. Svoboda P, Kantorová I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?. Hepatogastroenterology 2007;54(74):359-63. [4780910; PUBMED: 17523274]
13. Bodmann KF, Schenker M, Heinlein W, Wilke MH. Procalcitonin as a tool for the assessment of successful therapy of severe sepsis: an analysis using clinical routine data [Eine Untersuchung mit klinischen Routinedaten]. Medizinische Klinik, Intensivmedizin und Notfallmedizin 2016;Epub ahead of print:1-8. [4780912; PUBMED: 27376540]
14. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. The Lancet 2010;375(9713):463-74. [4780914; PUBMED: 20097417]
15. Bréchot N, Hékimian G, Chastre J, Luyt CE. Procalcitonin to guide antibiotic therapy in the ICU. International Journal of Antimicrobial Agents 2015;46(Suppl 1):S19-24. [4780916; PUBMED: 26607343]
16. Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? Infection control and hospital epidemiology. Infection Control and Hospital Epidemiology 2015;36(3):265-72. [4780918; DOI: 10.1017/ice.2014.60]
17. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr T, Andersen MH, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open 2012;2(2):e000635. [4780920; PUBMED: 22411933]
18. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Critical Care Medicine 2011;39(9):2048-58. [4780921; PUBMED: 21572328]
19. Jensen JU, Lundgren B, Hein L, Mohr T, Petersen PL, Andersen LH, et al. The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infectious Diseases 2008;8:91. [4780922; PUBMED: 18620598]
20. Johansen ME, Jensen JU, Bestle MH, Hein L, Lauritsen AØ, Tousi H, et al. The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. Public Library of Science PLoS ONE 2013;8(11):e81477. [4780923; PUBMED: 24312305]
21. Kiehntopf M, Hutagalung R, Bloos F, Oppert M, Grundling M, Weiler N, et al. Prognostic impact of procalcitonin in severe sepsis and septic shock: results of the VISEP study. Infection 2011;39(Suppl 2):S114-5. [CENTRAL: CN-01005880; 4780925]
22. Kip MM, Kusters R, IJzerman MJ, Steuten LM. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. Journal of Medical Economics 2015;18(11):944-53. [4780927; PUBMED: 26105574]
23. Kolici N, Tushe E, Dedej G, Kolici E, Foto E. Role of semi-quantitative procalcitonin test kit versus CRP to "rule out" neonatal sepsis. Intensive Care Medicine 2013;41(1):S189-90. [CENTRAL: CN-01060306; 4780929; DOI: 10.1007/s00134-013-2950-8]
24. Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Critical Care Medicine 2010;38(11):2229-41. [4780931; PUBMED: 20729729]
25. Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Critical Care Medicine 2012;40(8):2304-9. [4780933; PUBMED: 22809906]
26. Lima SS, Nobre V, de Castro Romanelli RM, Clemente WT, da Silva BittencourtHN, Melo AC, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Annals of Hematology 2016;95(7):1169-76. [4780935; PUBMED: 27118539]
27. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. Burns 2011;37(4):549-58. [4780937; PUBMED: 20537467]
28. Pantelidou IM, Giamarellos-Bourboulis EJ. Can procalcitonin monitoring reduce the length of antibiotic treatment in bloodstream infections?. International Journal of Antimicrobial Agents 2015;48(Suppl 1):S10-2. [4780939; PUBMED: 26686272]
29. Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock: a systematic review and meta-analysis. Critical Care (London, England) 2013;17(6):R291. [4780941; PUBMED: 24330744]
30. Sandifer JP, Jones AE. Can procalcitonin levels guide antibiotic therapy in bacterial infections and reduce antibiotic over consumption without having a negative effect on clinical outcomes?. Annals of Emergency Medicine 2012;60(3):370-1. [4780943; PUBMED: 22305332]
31. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine 2011;171(15):1322-31. [4780945; PUBMED: 21824946]
32. Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Current Opinion in Critical Care 2013;19(5):453-60. [4780947; PUBMED: 23817026]
33. Soni NJ, Samson DJ, Galaydick JL, Vats V, Huang ES, Aronson N, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. Journal of Hospital Medicine 2013;8(9):530-40. [4780949; PUBMED: 23955852]
34. Stocker M, Hop WC, van Rossum AM. Neonatal Procalcitonin Intervention Study (NeoPInS): effect of procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early-onset sepsis: a multi-centre randomized superiority and non-inferiority intervention study. BioMed Central Pediatrics 2010;10:89. [4780951; PUBMED: 21143869]
35. Stocker M, Fontana M, El Helou S, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010;97(2):165-74. [4780953; PUBMED: 19776651]
36. Ternhag A, Cars O, Norman C, Struwe J. Antibiotics or not - procalcitonin can guide therapeutic choices. At least at the emergency department for adults with lower respiratory tract infection [Antibiotika eller inte - prokalcitonin kan vägleda behandlingsval]. Lakartidningen 2010;107(15):98. [4780955; MEDLINE: 20464915]
37. Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technology Assessment (Winchester, England) 2015;19(96):v-xxv, 1-236. [4780957; PUBMED: 26569153]
38. Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Internal Medicine 2016;176(9):1266-76. [4780959; PUBMED: 27428731]
39. Assink-de Jong E, de Lange DW, van Oers JA, Nijsten MW, Twisk JW, Beishuizen A. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients - calculated sample size: 1816 patients. BioMed Central Infectious Diseases 2013;13:178. [4780961; PUBMED: 23590389]
40. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. The Lancet Infectious Diseases 2016;16(7):819-27. [4780962; PUBMED: 26947523]
41. Najafi A, Khodadadian A, Sanatkar M, Moharari RS, Etezadi F, Ahmadi A, et al. The comparison of procalcitonin guidance administer antibiotics with empiric antibiotic therapy in critically ill patients admitted in intensive care unit. Acta Medica Iranica 2015;53(9):562-7. [4780964; PUBMED: 26553084]
42. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992;20(6):864-74. [PUBMED: 1597042]
43. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. The Lancet 2010;376(9749):1339-46. [PUBMED: 20934212]
44. Assunção M, Akamine N, Cardoso GS, Mello PV, Teles JM, Nunes AL, et al. Survey on physicians' knowledge of sepsis: do they recognize it promptly?. Journal of Critical Care 2010;25(4):545-52. [PUBMED: 20646902]
45. Azevedo JR, Torres OJ, Czeczko NG, Tuon FF, Nassif PA, Souza GD. Procalcitonin as a prognostic biomarker of severe sepsis and septic shock. Revista do Colégio Brasileiro de Cirurgiões 2012;39(6):456-61. [PUBMED: 23348640]
46. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Critical Care Medicine 2008;36(3):941-52. [PUBMED: 18431284]
47. Bone RC, Balk RA, Cerra FB. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101(6):1644-55. [PUBMED: 1303622]
48. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 2009;136(5 Suppl):e28. [PUBMED: 20162763]
49. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
50. Chalupa P, Beran O, Herwald H, Kaspříková N, Holub M. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection 2011;39(5):411-7. [PUBMED: 21720792]
51. Christensen PM, Kristiansen IS. Number-needed-to-treat (NNT) - needs treatment with care. Basic & Clinical Pharmacology & Toxicology 2006;99(1):12-6. [PUBMED: 16867164]
52. Cuthbertson BH, Elders A, Hall S, Taylor J, Maclennan G, McKirdy F, et al. Mortality and quality of life in the five years after severe sepsis. Critical Care 2013;17(2):R70. [PUBMED: 23587132]
53. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock 2012. Intensive Care Medicine 2013;39(2):165-228. [PUBMED: 23361625]
54. García de Guadiana-Romualdo LM, Rebollo-Acebes S, Esteban-Torrella P, Jiménez-Sánchez R, Hernando-Holgado A, Ortín-Freire A, et al. Prognostic value of lipopolysaccharide binding protein and procalcitonin in patients with severe sepsis and septic shock admitted to intensive care [Valor pronóstico de la proteína fijadora de lipopolisácaridos y la procalcitonina en pacientes con sepsis grave y shock séptico ingresados en una unidad de cuidados intensivos]. Medicina Intensiva 2015;39(4):207-12. [PUBMED: 24953001]
55. Garnacho-Montero J, Huici-Moreno MJ, Gutiérrez-Pizarraya A, López I, Márquez-Vácaro JA, Macher H, et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Critical Care 2014;18(3):R116. [PUBMED: 24903083]
56. Gendrel D, Raymond J, Coste J, Moulin F, Lorrot M, Guérin S, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. The Pediatric Infectious Disease Journal 1999;18(10):875-81. [PUBMED: 10530583]
57. McMaster University. GRADEpro. McMaster University, 2014.
58. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians. BMJ 2008;336(7651):995-8. [PUBMED: 18456631]
59. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
60. Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013;346:e5793. [PUBMED: 23386361]
61. Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clinical Microbiology and Infection 2015;21(5):474-81. [PUBMED: 25726038]
62. Hohn A, Schroeder S, Gehrt A, Bernhardt K, Bein B, Wegscheider K, et al. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BioMed Central Infectious Diseases 2013;13:158. [PUBMED: 23547790]
63. Hohn A, Heising B, Hertel S, Baumgarten G, Hochreiter M, Schroeder S. Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis. Infection 2015;43(4):405-12. [PUBMED: 25588968]
64. Hosein S, Udy AA, Lipman J. Physiological changes in the critically ill patient with sepsis. Current Pharmaceutical Biotechnology 2011;12(12):1991-5. [PUBMED: 21554219]
65. Jawad I, Lukšić I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. Journal of Global Health 2012;2(1):10404. [PUBMED: 23198133]
66. Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettilä V, Finnsepsis Study Group. Long-term outcome and quality-adjusted life years after severe sepsis. Critical Care Medicine 2009;37(4):1268-74. [PUBMED: 19242321]
67. Kenzaka T, Okayama M, Kuroki S, Fukui M, Yahata S, Hayashi H, et al. Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis. International Journal of General Medicine 2012;5:483-8. [PUBMED: 22701089]
68. Kicinski M. Publication bias in recent meta-analyses. PLoS ONE 2013;8(11):e81823. [DOI: 10.1371/journal.pone.0081823]
69. Klein Klouwenberg PM, Ong DS, Bonten MJ, Cremer OL. Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria. Intensive Care Medicine 2012;38(5):811-9. [PUBMED: 22476449]
70. Kuehn BM. Guideline promotes early, aggressive sepsis treatment to boost survival. JAMA 2013;309(10):969-70. [PUBMED: 23483148]
71. Kumar A. Early antimicrobial therapy in severe sepsis and septic shock. Current Infectious Disease Reports 2010;12(5):336-44. [PUBMED: 21308515]
72. Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Critical Care Medicine 2012;40(3):754-61. [PUBMED: 21963582]
73. Leli C, Cardaccia A, Ferranti M, Cesarini A, D'Alò F, Ferri C, et al. Procalcitonin better than C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in predicting DNAemia in patients with sepsis. Scandinavian Journal of Infectious Diseases 2014;46(11):745-52. [PUBMED: 25195647]
74. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Medicine 2003;29(4):530-8. [PUBMED: 12664219]
75. Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA. Predictors of survival in sepsis: what is the best inflammatory marker to measure?. Current Opinion in Infectious Diseases 2012;25(3):328-36. [PUBMED: 22421751]
76. Liu D, Su L, Han G, Yan P, Xie L. Prognostic value of procalcitonin in adult patients with sepsis: a systematic review and meta-analysis. PLoS ONE 2015;10(6):e0129450. [PUBMED: 26076027]
77. Machado FR, Salomão R, Rigato O, Ferreira EM, Schettino G, Mohovic T, et al. Late recognition and illness severity are determinants of early death in severe septic patients. Clinics (Sao Paulo) 2013;68(5):586-91. [PUBMED: 23778420]
78. Maravić-Stojković V, Lausević-Vuk L, Jović M, Ranković A, Borzanović M, Marinković J. Procalcitonin-based therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: a randomized controlled trial. Srpski Arhiv za Celokupno Lekarstvo 2011;139(11-12):736-42. [PUBMED: 22338468]
79. Maseda E, Suarez-de-la-Rica A, Anillo V, Tamayo E, García-Bernedo CA, Ramasco F, et al. Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: a multicenter retrospective study. Journal of Critical Care 2015;30(3):537-42. [PUBMED: 25600574]
80. Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Medicine 2012;38(6):940-9. [PUBMED: 22538461]
81. McCann FJ, Chapman SJ, Yu WC, Maskell NA, Davies RJ, Lee YC. Ability of procalcitonin to discriminate infection from non-infective inflammation using two pleural disease settings. PLoS ONE 2012;7(12):e49894. [PUBMED: 23251353]
82. Morgenthaler NG, Struck J, Chancerelle Y, Weglöhner W, Agay D, Bohuon C, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Hormone and Metabolic Research 2003;35(5):290-5. [PUBMED: 12915998]
83. Nargis W, Ibrahim M, Ahamed BU. Procalcitonin versus C-reactive protein: usefulness as biomarker of sepsis in ICU patient. International Journal of Critical Illness and Injury Science 2014;4(3):195-9. [PUBMED: 25337480]
84. Redl H, Schlag G, Tögel E, Assicot M, Bohuon C. Procalcitonin release patterns in a baboon model of trauma and sepsis: relationship to cytokines and neopterin. Critical Care Medicine 2000;28(11):3659-63. [PUBMED: 11098970]
85. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
86. Rivers EP, Katranji M, Jaehne KA, Brown S, Abou Dagher G, Cannon C, et al. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiologica 2012;78(6):712-24. [PUBMED: 22447123]
87. Rodger M, Ramsay T, Fergusson D. Diagnostic randomized controlled trials: the final frontier. Trials Journal 2012;13:137. [PUBMED: 22897974]
88. Salluh JI, Lisboa T. C-reactive protein in community-acquired sepsis: you can teach new tricks to an old dog. Critical Care 2011;15(5):186. [PUBMED: 21955725]
89. Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, et al. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Medicine 1995;Suppl 2:S244-9. [PUBMED: 8636531]
90. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD007498.pub2]
91. Shaikh N, Evron J, Leeflang MM. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD009185]
92. Silva E, Pedro Mde A, Sogayar AC, Mohovic T, Silva CL, Janiszewski M, et al. Brazilian Sepsis Epidemiological Study (BASES study). Critical Care 2004;8(4):R251-60. [DOI: 10.1186/cc2892; PUBMED: 15312226]
93. Suresh G, Soll R. The diagnostic accuracy of C-reactive protein and procalcitonin for neonatal sepsis (registered Cochrane title). http://www.archie.cochrane.org/search.jsp (accessed 31 January 2014).
94. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. The Lancet Infectious Diseases 2007;7(3):210-7. [PUBMED: 17317602]
95. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37(6):497-507. [PUBMED: 19826761]
96. Tasdelen Fisgin N, Aliyazicioglu Y, Tanyel E, Coban AY, Ulger F, Zivalioglu M, et al. The value of neopterin and procalcitonin in patients with sepsis. Southern Medical Journal 2010;103(3):216-9. [PUBMED: 20134373]
97. te Witt R, Hassing RJ, Petit PP, van Belkum A, van Genderen PJ. Procalcitonin and neopterin levels do not accurately distinguish bacterial from viral infections in ill-returned travellers with fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 2012;106(4):264-6. [PUBMED: 22357400]
98. Tsalik EL, Jaggers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, et al. Discriminative value of inflammatory biomarkers for suspected sepsis. Journal of Emergency Medicine 2012;43(1):97-106. [PUBMED: 22056545]
99. Uusitalo-Seppälä R, Koskinen P, Leino A, Peuravuori H, Vahlberg T, Rintala EM. Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6. Scandinavian Journal of Infectious Diseases 2011;43(11-12):883-90. [PUBMED: 21892899]
100. Vaughan-Sarrazin MS, Bayman L, Cullen JJ. Costs of postoperative sepsis: the business case for quality improvement to reduce postoperative sepsis in Veterans Affairs hospitals. Archives of Surgery 2011;146(8):944-51. [PUBMED: 21502443]
101. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. The Lancet Infectious Diseases 2013;13(5):426-35. [PUBMED: 23375419]
102. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75. [PUBMED: 18083463]
103. Zannoni A, Giunti M, Bernardini C, Gentilini F, Zaniboni A, Bacci ML, et al. Procalcitonin gene expression after LPS stimulation in the porcine animal model. Research in Veterinary Science 2012;93(2):921-7. [PUBMED: 22001598]
104. Silva BNG, Andriolo RB, Salomão R, Atallah ÁN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adult patients with sepsis, severe sepsis and septic shock. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010959]